What is the recommended treatment for esophagitis or esophageal irritation?

Treatment of Esophagitis

For erosive esophagitis from GERD, initiate a proton pump inhibitor (PPI) at standard dosing once daily for 8 weeks, then continue long-term daily PPI therapy indefinitely to prevent recurrence, as healing rates exceed 80% and recurrence rates approach 80% within one year without maintenance therapy. 1, 2, 3

Erosive Esophagitis (GERD-Related)

Initial Treatment

• Start with a PPI as first-line therapy using standard doses: omeprazole 20 mg, lansoprazole 30 mg, pantoprazole 40 mg, or rabeprazole 20 mg once daily for 8 weeks 1, 2, 3
• PPIs are significantly more effective than H2-receptor antagonists, which are more effective than placebo, for both healing esophagitis and providing symptomatic relief 1, 4
• If healing is incomplete after 8 weeks in adults, continue treatment for an additional 8 weeks 1, 3
• For inadequate response to once-daily dosing, escalate to twice-daily PPI dosing before considering treatment failure 1

Maintenance Therapy

• Long-term daily PPI therapy is mandatory for all patients with healed erosive esophagitis to prevent recurrence 1, 2
• Recurrence rates of erosive disease reach 80% at one year without maintenance therapy 1, 4
• Do NOT use on-demand or intermittent PPI dosing in patients with documented erosive esophagitis—recurrence rates are unacceptably high compared to continuous daily therapy 1, 2
• Titrate maintenance therapy down to the lowest effective dose based on symptom control, but maintain daily dosing 1
• H2-receptor antagonists are ineffective for maintenance and appear no better than placebo in preventing recurrence 1, 4

Common Pitfalls

• Avoid adding a nocturnal H2RA to twice-daily PPI therapy—there is no evidence of improved efficacy 1
• Consider patients whose heartburn has not responded to twice-daily PPI therapy as treatment failures requiring endoscopic evaluation 1
• Do not broadly recommend lifestyle modifications to all patients; tailor specific interventions (weight loss, head-of-bed elevation, avoiding late meals) only to patients whose history suggests benefit 1

Eosinophilic Esophagitis (EoE)

First-Line Treatment Options

• Initiate PPI therapy at twice-daily dosing (e.g., omeprazole 20-40 mg twice daily in adults, 1 mg/kg per dose twice daily in children) for 8-12 weeks as first-line treatment due to favorable safety profile, low cost, and substantial efficacy 1, 2, 5, 6
• PPIs are now recognized as legitimate EoE treatment, not merely a diagnostic exclusion criterion, as PPI-responsive esophageal eosinophilia is clinically, endoscopically, histologically, and molecularly indistinguishable from classic EoE 5, 6
• Alternatively, topical corticosteroids (swallowed fluticasone or budesonide) are highly effective and carry a strong recommendation based on moderate-quality evidence 1, 2, 6

Mandatory Endoscopic Assessment

• Perform repeat endoscopy with esophageal biopsies from multiple sites after 8-12 weeks of therapy while the patient is still on treatment—symptom improvement does NOT reliably predict histologic healing 1, 2, 5, 6
• Histologic remission is defined as <15 eosinophils per high-power field (0.3 mm²) 5, 6
• Obtain a minimum of 6 biopsies from different esophageal sites to assess response 5
• Failure to confirm mucosal healing allows persistent eosinophilic inflammation despite apparent clinical benefit, risking ongoing fibrosis and stricture formation 2

Maintenance Therapy

• Continue PPI or topical corticosteroid therapy indefinitely in patients who achieve histologic remission, as relapse rates are extremely high after withdrawal 1, 2, 6
• Long-term maintenance prevents recurrent dysphagia, food impaction, and esophageal stricture formation 2, 6
• Limited data suggest PPIs maintain sustained histologic response better than low-dose topical steroids 1

Dietary Management

• Six-food elimination diet (milk, wheat, egg, soy, nuts, fish/shellfish) achieves 72-79% histologic remission but has lower patient acceptance 2, 6
• Two-food elimination (milk + wheat) achieves 43% remission with better compliance 2
• All elimination diets require supervision by an experienced dietitian to prevent nutritional deficiencies and monitor growth in children 2
• Allergy testing (skin prick, serum IgE, patch testing) has limited predictive value (~45.5% efficacy) and should NOT guide food elimination 2

Endoscopic Dilation for Strictures

• In patients with dysphagia from EoE-associated strictures, perform endoscopic dilation using a conservative approach 1, 2, 6
• Dilation improves dysphagia in 87% of patients but does NOT address underlying inflammation 1
• Perforation rate is 0.4%, hospitalization 1.2%, with most perforations occurring before 2009 when more aggressive techniques were used 1
• Combine dilation with anti-inflammatory therapy (PPIs or topical steroids) for optimal outcomes 2, 6

Critical Pitfall

• Do not assume symptom resolution equals histological healing—endoscopic assessment with biopsies is mandatory, as 41% of patients report symptomatic improvement without true histologic remission 2, 6

Infectious Esophagitis (Candidal)

Treatment

• Systemic antifungal therapy is required for effective treatment of esophageal candidiasis 1
• Oral fluconazole for 14-21 days is the drug of choice due to high efficacy and excellent tolerability 1
• Itraconazole oral solution for 14-21 days is equally effective but less well tolerated 1
• Topical therapy (clotrimazole troches, nystatin) is adequate only for oropharyngeal candidiasis, not esophageal disease 1
• IV caspofungin or IV voriconazole are effective alternatives but have higher relapse rates compared to fluconazole 1

Diagnostic Approach

• A diagnostic trial of antifungal therapy is appropriate before endoscopy in patients with typical symptoms of esophageal candidiasis 1
• Response to therapy should occur within 48-72 hours 1